Download PDF
Pharmacopsychiatry 2005; 38(2): 78-86
DOI: 10.1055/s-2005-837807
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Tolerability of Hypericum Extract STW3 in Long-term Treatment with a Once-daily Dosage in Comparison with Sertraline

M. Gastpar1 , A. Singer2 , K. Zeller3
  • 1General Psychiatric Hospital, Dept. of Psychiatry and Psychotherapy, University of Essen, Germany
  • 2EPA Euro Pharma Auftragsforschung GmbH, Kronberg, Germany
  • 3Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
Further Information

Publication History

Received: 1.10.2003 Revised: 3.12.2003

Accepted: 8.8.2004

Publication Date:
02 March 2005 (online)

Also available at
    Permissions and Reprints

Objective: The objective of this double-blind, multi-center clinical study was to demonstrate the non-inferiority of hypericum extract versus sertraline in the treatment of moderate depression. Methods: A total of 241 patients with a diagnosis of moderate depressive disorder (according to ICD-10 criteria) were randomized with either 50 mg sertraline or 612 mg hypericum extract (hypericum group n = 123; sertraline group n = 118). According to the study protocol, 200 patients were treated for at least 12 weeks (n = 102 hypericum extract; n = 98 sertraline); 81 patients in the hypericum group and 80 in the sertraline group were treated after week 12 for an additional 12 weeks. Thus, most patients were treated for a period of 6 months. The primary efficacy variable was the 17-item HAMD total score at the end of the first 12-week double-blind treatment period. Results: After the first 12-week treatment period, the HAMD score decreased from almost identical initial values (22.0 ± 1.1 for hypericum and 22.1 ± 1.1 points for sertraline) to 8.3 ± 5.5 points (hypericum) and 8.1 ± 5.6 points (sertraline) (mean ± SD) in the patients treated per-protocol (PP) population. The statistical test for non-inferiority (boundary δ = 3) revealed that hypericum extract is not inferior to sertraline (P < 0.0001). The mean difference between the treatments was 0.1995 points, with a corresponding one-sided 97.5 % confidence interval (-∞, 1.3772). In patients who continued treatment in the follow-up phase, the HAMD score at the end of the study was 5.7 ± 4.8 points (hypericum group) and 7.1 ± 6.3 points (sertraline group). Comparable improvement was also found for the von Zerssen’s Adjective Mood Scale (BfS) and CGI during the first and second 12-week treatment period in both treatment groups. With 68.6 % of patients in the hypericum group and 70.4 % in the sertraline group, the percentage of patients rated as responders did not differ significantly between treatment groups (12 weeks). The adverse events of 12 patients in the hypericum group (9.8 %) and of 16 patients in the sertraline group (13.6 %) were possibly related to study medication. No basic differences in the treatment groups were observed and no interaction with concomitant medication was documented. In most cases, the investigators assessed the tolerability of hypericum extract and sertraline as ”good” or ”very good.” Conclusions: The results indicate that hypericum extract STW 3 is not inferior to sertraline and that it is a well-tolerated drug for the treatment of moderate depression. These favorable effects were achieved with a once-daily dose of 612 mg of hypericum extract given for up to 24 weeks.

References

  • 1 Barnes J, Anderson L A, Phillipson J D. St John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties.  J Pharm Pharmacol. 2001;  53 (5) 83-600
    CrossrefPubMedGoogle Scholar
  • 2 Biber A, Fischer H, Romer A, Chatterjee S S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers.  Pharmacopsychiatry. 1998;  31 Suppl 1 6-43
    PubMedGoogle Scholar
  • 3 Bracher A. Johanniskraut 1x täglich: Wirkung klinisch belegt/HYP611-Studie bestätigt Wirksamkeit.  Verlagsbeilage Ärztliche Praxis. 2001;  51 1-4
    PubMedGoogle Scholar
  • 4 Brenner R, Azbel V. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomised pilot study.  Clinical therapeutics. 2000;  22 411-419
    CrossrefPubMedGoogle Scholar
  • 5 Brockmöller J, Reum T, Bauer S, Kerb R, Hübner W -D, Roots I. Hypericin and Pseudohypericin: Pharmacokinetics and Effects on Photosensitivity in Humans.  Pharmacopsychiat.. 1997;  30 Supplement 94-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test.  Planta Medica. 2000;  66 3-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Med. 1998;  64 (4) 291-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Dienel A. Wirksamkeit von Hypericum-Extrakt WS 5570 bei Patienten mit depressiven Störungen. In : Schulz V, Rietbrock N, Roots I, Loew D (eds) Phytopharmaka VII - Forschung und klinische Anwendung. Darmstadt; Steinkopf 2002-10-22
    Google Scholar
  • 9 DSM-IV . Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). The American Psychiatric Association. Washington; 1994: 339-345
    Google Scholar
  • 10 EME A. Note for Guidance on clinical investigation of medicinal products in the treatment of depression. CPMP/EWP/518/97. The European Agency for the Evaluation of Medicinal Products 2002
    Google Scholar
  • 11 ESCO P. Hyperici herba St. John’s wort. ESCOP Monographie 1996
    Google Scholar
  • 12 Fava M, Rankin M. Sexual functioning and SSRIs.  J Clin Psychiatry. 2002;  63 Suppl 5 13-6
    PubMedGoogle Scholar
  • 13 Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md; National Institutes of Mental Health 1976 Publication ADM 76 - 338
    Google Scholar
  • 14 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 6 - 62
    PubMedGoogle Scholar
  • 15 Hübner W D, Arnoldt K H. Johanniskraut-Einjahresstudie.  Zeitschrift für Phytotherapie. 2000;  21 06 - 310
    PubMedGoogle Scholar
  • 16 Hypericum Depression Trial Study G roup. Effect of Hypericum perforatum (St John's Wort) in major depressive disorders - A randomized controlled trial.  JAMA. 2002;  287 1807-1814
    CrossrefPubMedGoogle Scholar
  • 17 IC D -10. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. Geneva; World Health Organization 1992
    Google Scholar
  • 18 Kalb R, Trautmann-Sponsel R D, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial.  Pharmacopsychiatry.. 2001;  34 (3) 96-103
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kasper S. Hypericum perforatum - a review of clinical studies.  Pharmacopsychiat. 2001;  34 Suppl 1 51-55
    PubMedGoogle Scholar
  • 20 Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.  Antimicrob Agents Chemother.. 1996ep;  40 (9) 2087-93.
    PubMedGoogle Scholar
  • 21 Kommission E. Monographie Hyperici herba (Johanniskraut). Bundesanzeiger 228 05.12.1984
    Google Scholar
  • 22 König W, Laux G. Trizyklische Antidepressiva. In: Riederer P, Laux G, Poldinger W (eds) Neuropsychopharmaka. Band 3 Springer-Verlag Berlin-Heidelberg-New York; 1993
    Google Scholar
  • 23 Kötter H U, Möller H J, Hampel H. Sertralin: Ein moderner selektiver Serotonin-Wiederaufnahmehemmer in der antidepressiven Therapie. Arzneimitteltherapie; 17.  Jahrgang Heft. 1999;  12 395-401
    PubMedGoogle Scholar
  • 24 Lepine J P, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society).  Int Clin Psychopharmacol. 1997;  12 (1) 19-29
    PubMedGoogle Scholar
  • 25 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St John’s wort for depression - an overview and meta-analysis of randomised clinical trials.  BMJ. 1996;  313 253-258
    PubMedGoogle Scholar
  • 26 Markowitz J S, Donovan J L, DeVane C L, Taylor R M, Ruan Y, Wang J S, Chavin K D. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA.  2003 Sep. 17;  290 (11) 1500-4
    PubMedGoogle Scholar
  • 27 Moscovitch A, Blashko C A, Eagles J M, Darcourt G, Thompson C, Kasper S, Lane R M. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 2003: [Epub ahead of print]
    Google Scholar
  • 28 Osterheider M, Schmidtke A, Beckmann H. Behandlung depressiver Syndrome mit Hypericum (Johanniskraut) - eine placebo-kontrollierte Doppelblindstudie.  Fortschritte der Neurologie/Psychiatrie. 1992;  60 210-211
    PubMedGoogle Scholar
  • 29 Philipp M, Kohen R, Hiller K O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.  BMJ. 1999;  319 1534-1539
    PubMedGoogle Scholar
  • 30 Rychlik R, Siedentop H, von den Driesch V, Kasper S. St. John’s wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily.  Fortschr Med Orig. 2001;  119 (3 - 4) 119-28
    PubMedGoogle Scholar
  • 31 Schmidt U, Sommer H. St. John’s wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved.  Fortschr Med. 1993;  111 (19) 339-42
    PubMedGoogle Scholar
  • 32 Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.  Int Clin Psychopharmacol. 2000;  15 (2) 61-8
    PubMedGoogle Scholar
  • 33 Schulz V. Clinical trials with hypericum extracts in patients with depression-results, comparisons, conclusions for therapy with antidepressant drugs.  Phytomedicine. 2002;  9 (5) 468-74
    CrossrefPubMedGoogle Scholar
  • 34 St. John’s Wort. (Hypericum perforatum). Quality Control, Analytic and Therapeutic Monograph. American Herbal Pharmacopoeia and Therapeutic Compendium 1997: 1-32
    Google Scholar
  • 35 Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers.  J Geriatr Psychiatry Neurol. 1994;  7 Suppl 1 S47-53
    PubMedGoogle Scholar
  • 36 Tylee A, Gastpar M, Lepine J P, Mendlewicz J. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee.  Int Clin Psychopharmacol. 1999;  14 (3) 139-51.
    PubMedGoogle Scholar
  • 37 van Gurp G, Meterissian G B, Haiek L N, McCusker J, Bellavance F. St John’s wort or sertraline? Randomized controlled trial in primary care.  Can Fam Physician. 2002;  48 905-12
    PubMedGoogle Scholar
  • 38 Volz H P. Controlled clinical trials of hypericum extracts in depressed patients - an overview.  Pharmacopsychiat.. 1997;  30 72-76
    PubMedGoogle Scholar
  • 39 Vorbach E U, Hübner W D, Arnoldt K H. Wirksamkeit und Verträglichkeit des Hypericum-Extraktes LI 160 im Vergleich mit Imipramin.  Nervenheilkunde. 1993;  12 90-296
    PubMedGoogle Scholar
  • 40 WH O. Herba hyperici; WHO monographs on selected medicinal plants. Volume 2
    Google Scholar
  • 41 Woelk H. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial.  BMJ. 2000;  321 (7260) 536-9
    CrossrefPubMedGoogle Scholar
  • 42 Yyldyz A, Sachs G S. Administration of antidepressants. Single versus split dosing: a meta-analysis.  J Affect Disord. 2001;  66 (2 - 3) 199-206
    CrossrefPubMedGoogle Scholar
  • 43 Zerssen D v on, Koeller D -M, Rey E -R. Die Befindlichkeits-Skala (B-S) - ein einfaches Instrument zur Objektivierung von Befindlichkeits-Störungen, insbesondere im Rahmen von Längsschnitt-Untersuchungen.  Arzneimittel-Forsch.. 1970;  20 915-918
    PubMedGoogle Scholar

Markus Gastpar, MD

Professor and Medical Director

Dept. of Psychiatry and Psychotherapy

University of Duisburg-Essen

Virchowstr. 174

D-45147 Essen

Email: m.gastpar@uni-essen.de

      >